Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
• Pfizer’s review of Lipitor begins in June and remains undecided. The incumbent, Merkley + Partners, is eliminated in September, leaving three contenders: JWT, The Kaplan Thaler Group and mcgarrybowen. Billings are estimated at $60-80 million.
• In December 2004, the FDA demands that AstraZeneca pull ads for its anti-cholesterol drug Crestor, calling its safety claims “misleading.” The following month, Crestor shifts from WPP’s CommonHealth to Saatchi & Saatchi Consumer Healthcare. Spending from January through September this year falls to $120 million, down from $130 in the same period last year, per Nielsen Monitor-Plus.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in